Search research articles
Contact Us
Filters
Showing results (171-180 of 180) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 180 results.
Nature Communications
|
October 6, 2020
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency
Melanie Werner-Klein, Ana Grujovic, Christoph Irlbeck, et al.
Blood Cancer Journal
|
January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Marc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
Leukemia
|
April 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network
Luca Fischer, Linmiao Jiang, Jan Dürig, et al.
The Lancet. Haematology
|
November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Blood Cancer Journal
|
October 20, 2025
Prospective systematic classification of causes of death in the course of multiple myeloma
Jia Xiang Jin, Britta Besemer, Büsranur Yilmaz, et al.
Academic Radiology
|
July 10, 2025
Automated Detection of Focal Bone Marrow Lesions From MRI: A Multi-center Feasibility Study in Patients with Monoclonal Plasma Cell Disorders
Markus Wennmann, Jessica Kächele, Arvin von Salomon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
Elias K Mai, Uta Bertsch, Ema Pozek, et al.
Investigative Radiology
|
May 24, 2023
Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics
Markus Wennmann, Wenlong Ming, Fabian Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2026
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 180) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 180 results.
Nature Communications
|
October 6, 2020
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency
Melanie Werner-Klein, Ana Grujovic, Christoph Irlbeck, et al.
Blood Cancer Journal
|
January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Marc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.
Leukemia
|
April 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network
Luca Fischer, Linmiao Jiang, Jan Dürig, et al.
The Lancet. Haematology
|
November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Blood Cancer Journal
|
October 20, 2025
Prospective systematic classification of causes of death in the course of multiple myeloma
Jia Xiang Jin, Britta Besemer, Büsranur Yilmaz, et al.
Academic Radiology
|
July 10, 2025
Automated Detection of Focal Bone Marrow Lesions From MRI: A Multi-center Feasibility Study in Patients with Monoclonal Plasma Cell Disorders
Markus Wennmann, Jessica Kächele, Arvin von Salomon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
Elias K Mai, Uta Bertsch, Ema Pozek, et al.
Investigative Radiology
|
May 24, 2023
Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics
Markus Wennmann, Wenlong Ming, Fabian Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2026
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Page
of 18